

Use of genistein in preventing memory loss and cognitive decline

About the solution

The subject of the invention is the preventive use of genistein to prevent the loss of memory and cognitive abilities in humans resulting from the natural processes of brain aging.

This novel use of genistein significantly reduces the accumulation in the brain of harmful, insoluble protein aggregates and deposits, including beta-amyloid, which occurs during the process of physiological aging.

The solution involves the oral administration of genistein to prevent memory loss and cognitive decline in humans.

The effectiveness of genistein therapy is influenced by the fact that it crosses the blood-brain barrier. A key element of the developed technology is the correct dose of genistein, carefully selected so that the autophagy process is strong enough to remove toxic protein forms, yet mild enough to prevent the body from destroying healthy forms of proteins.



Authors

prof. dr hab. Grzegorz Węgrzyn
dr Magdalena Podlacha
dr Dorota Myślińska
dr Irena Majkutewicz
dr Karolina Pierzynowska
dr Lidia Gaffke
mgr Zuzanna Cyske

Technology readiness level

TRL 4 – Technology validated in laboratory conditions

IP protection

The invention is the subject of a patent application
P.440896 UPRP
and international application
EP222208963.3 EPO

Cooperation opportunities

- Partnership in further research and commercialization